{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:24:54Z","timestamp":1794608694850,"version":"4.9.1"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1038\/s41380-023-02376-6","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T05:03:36Z","timestamp":1705381416000},"page":"847-857","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Monitoring synaptic pathology in Alzheimer\u2019s disease through fluid and PET imaging biomarkers: a comprehensive review and future perspectives"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6804-7858","authenticated-orcid":false,"given":"Simone","family":"Lista","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Santos-Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3908-0290","authenticated-orcid":false,"given":"Enzo","family":"Emanuele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6700-7491","authenticated-orcid":false,"given":"Nicola B.","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Gabelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"L\u00f3pez-Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7840-1061","authenticated-orcid":false,"given":"Juan","family":"Mart\u00edn-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunzia","family":"Maisto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7747-806X","authenticated-orcid":false,"given":"Camillo","family":"Imbimbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Caraci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno P.","family":"Imbimbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Nistic\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"key":"2376_CR1","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","volume":"12","author":"B Dubois","year":"2016","unstructured":"Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer\u2019s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12:292\u2013323.","journal-title":"Alzheimers Dement"},{"key":"2376_CR2","unstructured":"Gauthier S, Webster C, Servaes S, Morais JA, Rosa-Neto P. World Alzheimer Report 2022: life after diagnosis: navigating treatment, care and support. London: Alzheimer\u2019s Disease International; 2022."},{"key":"2376_CR3","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1126\/science.1074069","volume":"298","author":"DJ Selkoe","year":"2002","unstructured":"Selkoe DJ. Alzheimer\u2019s disease is a synaptic failure. Science. 2002;298:789\u201391.","journal-title":"Science"},{"key":"2376_CR4","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/ana.410300410","volume":"30","author":"RD Terry","year":"1991","unstructured":"Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer\u2019s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572\u201380.","journal-title":"Ann Neurol"},{"key":"2376_CR5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/BF01273157","volume":"103","author":"K Blennow","year":"1996","unstructured":"Blennow K, Bogdanovic N, Alafuzoff I, Ekman R, Davidsson P. Synaptic pathology in Alzheimer\u2019s disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. J Neural Transm (Vienna). 1996;103:603\u201318.","journal-title":"J Neural Transm (Vienna)"},{"key":"2376_CR6","doi-asserted-by":"publisher","first-page":"6391","DOI":"10.2174\/1381612811319360001","volume":"19","author":"M D\u2019Amelio","year":"2013","unstructured":"D\u2019Amelio M, Nistic\u00f2 R. Editorial Thematic Issue: Targeting synaptic dysfunction and neural connectivity in neurological and psychiatric disorders. Curr Pharm Des. 2013;19:6391\u20132.","journal-title":"Curr Pharm Des"},{"key":"2376_CR7","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3389\/fphar.2019.00778","volume":"10","author":"D Mango","year":"2019","unstructured":"Mango D, Saidi A, Cisale GY, Feligioni M, Corbo M, Nistic\u00f2 R. Targeting synaptic plasticity in experimental models of Alzheimer\u2019s disease. Front Pharm. 2019;10:778.","journal-title":"Front Pharm"},{"key":"2376_CR8","doi-asserted-by":"publisher","unstructured":"Aslam MM, Fan K-H, Lawrence E, Bedison MA, Snitz BE, DeKosky ST, et al. Genome-wide analysis identifies novel loci influencing plasma apolipoprotein E concentration and Alzheimer\u2019s disease risk. Mol Psychiatry. 2023. https:\/\/doi.org\/10.1038\/s41380-023-02170-4.","DOI":"10.1038\/s41380-023-02170-4"},{"key":"2376_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.neubiorev.2020.12.003","volume":"121","author":"Y Mimura","year":"2021","unstructured":"Mimura Y, Nishida H, Nakajima S, Tsugawa S, Morita S, Yoshida K, et al. Neurophysiological biomarkers using transcranial magnetic stimulation in Alzheimer\u2019s disease and mild cognitive impairment: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2021;121:47\u201359.","journal-title":"Neurosci Biobehav Rev"},{"key":"2376_CR10","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.3233\/JAD-201178","volume":"82","author":"D Mercer\u00f3n-Mart\u00ednez","year":"2021","unstructured":"Mercer\u00f3n-Mart\u00ednez D, Ibaceta-Gonz\u00e1lez C, Salazar C, Almaguer-Melian W, Bergado-Rosado JA, Palacios AG. Alzheimer\u2019s disease, neural plasticity, and functional recovery. J Alzheimers Dis. 2021;82:S37\u2013S50.","journal-title":"J Alzheimers Dis"},{"key":"2376_CR11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1177\/1073858419882619","volume":"26","author":"D Hefter","year":"2020","unstructured":"Hefter D, Ludewig S, Draguhn A, Korte M. Amyloid, APP, and electrical activity of the brain. Neuroscientist. 2020;26:231\u201351.","journal-title":"Neuroscientist"},{"key":"2376_CR12","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00221-011-2894-6","volume":"217","author":"M Korte","year":"2012","unstructured":"Korte M, Herrmann U, Zhang X, Draguhn A. The role of APP and APLP for synaptic transmission, plasticity, and network function: lessons from genetic mouse models. Exp Brain Res. 2012;217:435\u201340.","journal-title":"Exp Brain Res"},{"key":"2376_CR13","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1098\/rstb.2002.1240","volume":"358","author":"MJ Rowan","year":"2003","unstructured":"Rowan MJ, Klyubin I, Cullen WK, Anwyl R. Synaptic plasticity in animal models of early Alzheimer\u2019s disease. Philos Trans R Soc Lond B Biol Sci. 2003;358:821\u20138.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"2376_CR14","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/ene.15691","volume":"30","author":"C Motta","year":"2023","unstructured":"Motta C, Assogna M, Bonomi CG, Di Lorenzo F, Nuccetelli M, Mercuri NB, et al. Interplay between the catecholaminergic enzymatic axis and neurodegeneration\/neuroinflammation processes in the Alzheimer\u2019s disease continuum. Eur J Neurol. 2023;30:839\u201348.","journal-title":"Eur J Neurol"},{"key":"2376_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-01901-5","volume":"12","author":"K Henjum","year":"2022","unstructured":"Henjum K, Watne LO, Godang K, Halaas NB, Eldholm RS, Blennow K, et al. Cerebrospinal fluid catecholamines in Alzheimer\u2019s disease patients with and without biological disease. Transl Psychiatry. 2022;12:151.","journal-title":"Transl Psychiatry"},{"key":"2376_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14727","volume":"8","author":"A Nobili","year":"2017","unstructured":"Nobili A, Latagliata EC, Viscomi MT, Cavallucci V, Cutuli D, Giacovazzo G, et al. Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer\u2019s disease. Nat Commun. 2017;8:14727.","journal-title":"Nat Commun"},{"key":"2376_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s13195-021-00925-1","volume":"13","author":"A Sala","year":"2021","unstructured":"Sala A, Caminiti SP, Presotto L, Pilotto A, Liguori C, Chiaravalloti A, et al. In vivo human molecular neuroimaging of dopaminergic vulnerability along the Alzheimer\u2019s disease phases. Alzheimers Res Ther. 2021;13:187.","journal-title":"Alzheimers Res Ther"},{"key":"2376_CR18","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3233\/JAD-210171","volume":"82","author":"L Serra","year":"2021","unstructured":"Serra L, D\u2019Amelio M, Esposito S, Di Domenico C, Koch G, Marra C, et al. Ventral tegmental area disconnection contributes two years early to correctly classify patients converted to Alzheimer\u2019s disease: implications for treatment. J Alzheimers Dis. 2021;82:985\u20131000.","journal-title":"J Alzheimers Dis"},{"key":"2376_CR19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.neurobiolaging.2018.08.012","volume":"72","author":"L Serra","year":"2018","unstructured":"Serra L, D\u2019Amelio M, Di Domenico C, Dipasquale O, Marra C, Mercuri NB, et al. In vivo mapping of brainstem nuclei functional connectivity disruption in Alzheimer\u2019s disease. Neurobiol Aging. 2018;72:72\u201382.","journal-title":"Neurobiol Aging"},{"key":"2376_CR20","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.jalz.2011.05.2410","volume":"7","author":"CG Lyketsos","year":"2011","unstructured":"Lyketsos CG, Carrillo MC, Ryan JM, Khachaturian AS, Trzepacz P, Amatniek J, et al. Neuropsychiatric symptoms in Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:532\u20139.","journal-title":"Alzheimers Dement"},{"key":"2376_CR21","doi-asserted-by":"publisher","first-page":"964075","DOI":"10.3389\/fcell.2022.964075","volume":"10","author":"H Zhang","year":"2022","unstructured":"Zhang H, Jiang X, Ma L, Wei W, Li Z, Chang S, et al. Role of A\u03b2 in Alzheimer\u2019s-related synaptic dysfunction. Front Cell Dev Biol. 2022;10:964075.","journal-title":"Front Cell Dev Biol"},{"key":"2376_CR22","doi-asserted-by":"publisher","first-page":"7327","DOI":"10.1074\/jbc.M116.761189","volume":"292","author":"J Brito-Moreira","year":"2017","unstructured":"Brito-Moreira J, Lourenco MV, Oliveira MM, Ribeiro FC, Ledo JH, Diniz LP, et al. Interaction of amyloid-\u03b2 (A\u03b2) oligomers with neurexin 2\u03b1 and neuroligin 1 mediates synapse damage and memory loss in mice. J Biol Chem. 2017;292:7327\u201337.","journal-title":"J Biol Chem"},{"key":"2376_CR23","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1021\/pr300021e","volume":"11","author":"D Hartl","year":"2012","unstructured":"Hartl D, Schuldt V, Forler S, Zabel C, Klose J, Rohe M. Presymptomatic alterations in energy metabolism and oxidative stress in the APP23 mouse model of Alzheimer disease. J Proteome Res. 2012;11:3295\u2013304.","journal-title":"J Proteome Res"},{"key":"2376_CR24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3233\/JAD-210585","volume":"84","author":"X-Q Zhang","year":"2021","unstructured":"Zhang X-Q, Xu L, Yang S-Y, Hu L-B, Dong F-Y, Sun B-G, et al. Reduced synaptic transmission and intrinsic excitability of a subtype of pyramidal neurons in the medial prefrontal cortex in a mouse model of Alzheimer\u2019s disease. J Alzheimers Dis. 2021;84:129\u201340.","journal-title":"J Alzheimers Dis"},{"key":"2376_CR25","doi-asserted-by":"publisher","first-page":"1121.e1","DOI":"10.1016\/j.neurobiolaging.2011.09.021","volume":"33","author":"T Cassano","year":"2012","unstructured":"Cassano T, Serviddio G, Gaetani S, Romano A, Dipasquale P, Cianci S, et al. Glutamatergic alterations and mitochondrial impairment in a murine model of Alzheimer disease. Neurobiol Aging. 2012;33:1121.e1\u201312.","journal-title":"Neurobiol Aging"},{"key":"2376_CR26","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1126\/science.1098180","volume":"305","author":"T Maviel","year":"2004","unstructured":"Maviel T, Durkin TP, Menzaghi F, Bontempi B. Sites of neocortical reorganization critical for remote spatial memory. Science. 2004;305:96\u20139.","journal-title":"Science"},{"key":"2376_CR27","doi-asserted-by":"publisher","first-page":"12245","DOI":"10.1073\/pnas.211412398","volume":"98","author":"E Masliah","year":"2001","unstructured":"Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, et al. \u03b2-Amyloid peptides enhance \u03b1-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer\u2019s disease and Parkinson\u2019s disease. Proc Natl Acad Sci USA. 2001;98:12245\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2376_CR28","doi-asserted-by":"publisher","first-page":"7971","DOI":"10.1523\/JNEUROSCI.0775-16.2016","volume":"36","author":"B Spencer","year":"2016","unstructured":"Spencer B, Desplats PA, Overk CR, Valera-Martin E, Rissman RA, Wu C, et al. Reducing endogenous \u03b1-synuclein mitigates the degeneration of selective neuronal populations in an Alzheimer\u2019s disease transgenic mouse model. J Neurosci. 2016;36:7971\u201384.","journal-title":"J Neurosci"},{"key":"2376_CR29","doi-asserted-by":"publisher","first-page":"14966","DOI":"10.1073\/pnas.0406283101","volume":"101","author":"S Chandra","year":"2004","unstructured":"Chandra S, Fornai F, Kwon H-B, Yazdani U, Atasoy D, Liu X, et al. Double-knockout mice for \u03b1- and \u03b2-synucleins: effect on synaptic functions. Proc Natl Acad Sci USA. 2004;101:14966\u201371.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2376_CR30","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1111\/j.1460-9568.2007.05569.x","volume":"25","author":"S Liu","year":"2007","unstructured":"Liu S, Fa M, Ninan I, Trinchese F, Dauer W, Arancio O. Alpha-Synuclein involvement in hippocampal synaptic plasticity: role of NO, cGMP, cGK and CaMKII. Eur J Neurosci. 2007;25:3583\u201396.","journal-title":"Eur J Neurosci"},{"key":"2376_CR31","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1093\/hmg\/ddl242","volume":"15","author":"Y Fan","year":"2006","unstructured":"Fan Y, Limprasert P, Murray IVJ, Smith AC, Lee VM-Y, Trojanowski JQ, et al. \u03b2-synuclein modulates \u03b1-synuclein neurotoxicity by reducing \u03b1-synuclein protein expression. Hum Mol Genet. 2006;15:3002\u201311.","journal-title":"Hum Mol Genet"},{"key":"2376_CR32","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1074\/mcp.RA118.001290","volume":"18","author":"A Lle\u00f3","year":"2019","unstructured":"Lle\u00f3 A, N\u00fa\u00f1ez-Llaves R, Alcolea D, Chiva C, Balateu-Pa\u00f1os D, Colom-Cadena M, et al. Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer\u2019s disease cerebrospinal fluid. Mol Cell Proteom. 2019;18:546\u201360.","journal-title":"Mol Cell Proteom"},{"key":"2376_CR33","doi-asserted-by":"publisher","first-page":"e41275","DOI":"10.1371\/journal.pone.0041275","volume":"7","author":"L Zhong","year":"2012","unstructured":"Zhong L, Gerges NZ. Neurogranin targets calmodulin and lowers the threshold for the induction of long-term potentiation. PLoS ONE. 2012;7:e41275.","journal-title":"PLoS ONE"},{"key":"2376_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/srep11135","volume":"5","author":"A Petersen","year":"2015","unstructured":"Petersen A, Gerges NZ. Neurogranin regulates CaM dynamics at dendritic spines. Sci Rep. 2015;5:11135.","journal-title":"Sci Rep"},{"key":"2376_CR35","doi-asserted-by":"publisher","first-page":"11232","DOI":"10.1073\/pnas.210184697","volume":"97","author":"JH Pak","year":"2000","unstructured":"Pak JH, Huang FL, Li J, Balschun D, Reymann KG, Chiang C, et al. Involvement of neurogranin in the modulation of calcium\/calmodulin-dependent protein kinase II, synaptic plasticity, and spatial learning: a study with knockout mice. Proc Natl Acad Sci USA. 2000;97:11232\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2376_CR36","doi-asserted-by":"publisher","first-page":"10660","DOI":"10.1523\/JNEUROSCI.2213-04.2004","volume":"24","author":"K-P Huang","year":"2004","unstructured":"Huang K-P, Huang FL, J\u00e4ger T, Li J, Reymann KG, Balschun D. Neurogranin\/RC3 enhances long-term potentiation and learning by promoting calcium-mediated signaling. J Neurosci. 2004;24:10660\u20139.","journal-title":"J Neurosci"},{"key":"2376_CR37","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fnmol.2012.00020","volume":"5","author":"KH Braunewell","year":"2012","unstructured":"Braunewell KH. The visinin-like proteins VILIP-1 and VILIP-3 in Alzheimer\u2019s disease\u2014old wine in new bottles. Front Mol Neurosci. 2012;5:20.","journal-title":"Front Mol Neurosci"},{"key":"2376_CR38","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/ana.410270502","volume":"27","author":"ST DeKosky","year":"1990","unstructured":"DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer\u2019s disease: correlation with cognitive severity. Ann Neurol. 1990;27:457\u201364.","journal-title":"Ann Neurol"},{"key":"2376_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13195-020-00588-4","volume":"12","author":"M Colom-Cadena","year":"2020","unstructured":"The Synaptic Health Endpoints Working Group, Colom-Cadena M, Spires-Jones T, Zetterberg H, Blennow K, Caggiano A, et al. The clinical promise of biomarkers of synapse damage or loss in Alzheimer\u2019s disease. Alzheimers Res Ther. 2020;12:21.","journal-title":"Alzheimers Res Ther"},{"key":"2376_CR40","doi-asserted-by":"publisher","first-page":"117727192095031","DOI":"10.1177\/1177271920950319","volume":"15","author":"E Camporesi","year":"2020","unstructured":"Camporesi E, Nilsson J, Brinkmalm A, Becker B, Ashton NJ, Blennow K, et al. Fluid biomarkers for synaptic dysfunction and loss. Biomark Insights. 2020;15:117727192095031.","journal-title":"Biomark Insights"},{"key":"2376_CR41","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1017\/S1041610215000447","volume":"27","author":"Z-Y Wang","year":"2015","unstructured":"Wang Z-Y, Han Z-M, Liu Q-F, Tang W, Ye K, Yao Y-Y. Use of CSF \u03b1-synuclein in the differential diagnosis between Alzheimer\u2019s disease and other neurodegenerative disorders. Int Psychogeriatr. 2015;27:1429\u201338.","journal-title":"Int Psychogeriatr"},{"key":"2376_CR42","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1750-1326-9-48","volume":"9","author":"S Tu","year":"2014","unstructured":"Tu S, Okamoto S, Lipton SA, Xu H. Oligomeric A\u03b2-induced synaptic dysfunction in Alzheimer\u2019s disease. Mol Neurodegener. 2014;9:48.","journal-title":"Mol Neurodegener"},{"key":"2376_CR43","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3389\/fncel.2015.00464","volume":"9","author":"MJ Guerrero-Mu\u00f1oz","year":"2015","unstructured":"Guerrero-Mu\u00f1oz MJ, Gerson J, Castillo-Carranza DL. Tau oligomers: the toxic player at synapses in Alzheimer\u2019s disease. Front Cell Neurosci. 2015;9:464.","journal-title":"Front Cell Neurosci"},{"key":"2376_CR44","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1523\/JNEUROSCI.4970-06.2007","volume":"27","author":"GM Shankar","year":"2007","unstructured":"Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-\u03b2 protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866\u201375.","journal-title":"J Neurosci"},{"key":"2376_CR45","doi-asserted-by":"publisher","first-page":"S567","DOI":"10.3233\/JAD-179941","volume":"64","author":"EN Cline","year":"2018","unstructured":"Cline EN, Bicca MA, Viola KL, Klein WL. The amyloid-\u03b2 oligomer hypothesis: beginning of the third decade. J Alzheimers Dis. 2018;64:S567\u2013S610.","journal-title":"J Alzheimers Dis"},{"key":"2376_CR46","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1016\/j.neuron.2023.04.020","volume":"111","author":"M Colom-Cadena","year":"2023","unstructured":"Colom-Cadena M, Davies C, Sirisi S, Lee J-E, Simzer EM, Tzioras M, et al. Synaptic oligomeric tau in Alzheimer\u2019s disease \u2014 a potential culprit in the spread of tau pathology through the brain. Neuron. 2023;111:2170\u201383.e6. S0896627323003057.","journal-title":"Neuron"},{"key":"2376_CR47","doi-asserted-by":"publisher","first-page":"e26991","DOI":"10.7554\/eLife.26991","volume":"6","author":"D Puzzo","year":"2017","unstructured":"Puzzo D, Piacentini R, F\u00e1 M, Gulisano W, Li Puma DD, Staniszewski A, et al. LTP and memory impairment caused by extracellular A\u03b2 and Tau oligomers is APP-dependent. eLife. 2017;6:e26991.","journal-title":"eLife"},{"key":"2376_CR48","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1515\/tnsci-2015-0023","volume":"6","author":"S Jadhav","year":"2015","unstructured":"Jadhav S, Cubinkova V, Zimova I, Brezovakova V, Madari A, Cigankova V, et al. Tau-mediated synaptic damage in Alzheimer\u2019s disease. Transl Neurosci. 2015;6:214\u201326.","journal-title":"Transl Neurosci"},{"key":"2376_CR49","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.2174\/1570159X17666190603170511","volume":"17","author":"PL Cardozo","year":"2019","unstructured":"Cardozo PL, De Lima IBQ, Maciel EMA, Silva NC, Dobransky T, Ribeiro FM. Synaptic elimination in neurological disorders. Curr Neuropharmacol. 2019;17:1071\u201395.","journal-title":"Curr Neuropharmacol"},{"key":"2376_CR50","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.semcdb.2022.05.028","volume":"139","author":"J Griffiths","year":"2023","unstructured":"Griffiths J, Grant SGN. Synapse pathology in Alzheimer\u2019s disease. Semin Cell Dev Biol. 2023;139:13\u201323.","journal-title":"Semin Cell Dev Biol"},{"key":"2376_CR51","first-page":"871","volume":"5","author":"D Galasko","year":"2019","unstructured":"Galasko D, Xiao M, Xu D, Smirnov D, Salmon DP, Dewit N, et al. Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer\u2019s disease. Alzheimers Dement Transl Res Clin Inter. 2019;5:871\u201382.","journal-title":"Alzheimers Dement Transl Res Clin Inter"},{"key":"2376_CR52","doi-asserted-by":"publisher","first-page":"e2065","DOI":"10.1212\/WNL.0000000000012853","volume":"97","author":"M Mil\u00e0-Alom\u00e0","year":"2021","unstructured":"Mil\u00e0-Alom\u00e0 M, Brinkmalm A, Ashton NJ, Kvartsberg H, Shekari M, Operto G, et al. CSF synaptic biomarkers in the preclinical stage of Alzheimer disease and their association with MRI and PET: a cross-sectional study. Neurology. 2021;97:e2065\u201378.","journal-title":"Neurology"},{"key":"2376_CR53","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1523\/JNEUROSCI.10-12-03782.1990","volume":"10","author":"A Represa","year":"1990","unstructured":"Represa A, Deloulme J, Sensenbrenner M, Ben-Ari Y, Baudier J. Neurogranin: immunocytochemical localization of a brain-specific protein kinase C substrate. J Neurosci. 1990;10:3782\u201392.","journal-title":"J Neurosci"},{"key":"2376_CR54","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/BF02740632","volume":"15","author":"DD Gerendasy","year":"1997","unstructured":"Gerendasy DD, Gregor Sutcliffe J. RC3\/neurogranin, a postsynaptic calpacitin for setting the response threshold to calcium influxes. Mol Neurobiol. 1997;15:131\u201363.","journal-title":"Mol Neurobiol"},{"key":"2376_CR55","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nrn1647","volume":"6","author":"Z Xia","year":"2005","unstructured":"Xia Z, Storm DR. The role of calmodulin as a signal integrator for synaptic plasticity. Nat Rev Neurosci. 2005;6:267\u201376.","journal-title":"Nat Rev Neurosci"},{"key":"2376_CR56","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1038\/emboj.2009.273","volume":"28","author":"Y Hayashi","year":"2009","unstructured":"Hayashi Y. Long-term potentiation: two pathways meet at neurogranin. EMBO J. 2009;28:2859\u201360.","journal-title":"EMBO J"},{"key":"2376_CR57","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.brainres.2010.09.073","volume":"1362","author":"A Thorsell","year":"2010","unstructured":"Thorsell A, Bjerke M, Gobom J, Brunhage E, Vanmechelen E, Andreasen N, et al. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer\u2019s disease. Brain Res. 2010;1362:13\u201322.","journal-title":"Brain Res"},{"key":"2376_CR58","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.jalz.2014.10.009","volume":"11","author":"H Kvartsberg","year":"2015","unstructured":"Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, \u00d6hrfelt A, Andersson K, et al. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer\u2019s disease. Alzheimers Dement. 2015;11:1180\u201390.","journal-title":"Alzheimers Dement"},{"key":"2376_CR59","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1001\/jamaneurol.2015.1867","volume":"72","author":"MI Kester","year":"2015","unstructured":"Kester MI, Teunissen CE, Crimmins DL, Herries EM, Ladenson JH, Scheltens P, et al. Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease. JAMA Neurol. 2015;72:1275.","journal-title":"JAMA Neurol"},{"key":"2376_CR60","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1093\/brain\/awv267","volume":"138","author":"E Portelius","year":"2015","unstructured":"Portelius E, Zetterberg H, Skillb\u00e4ck T, T\u00f6rnqvist U, Andreasson U, Trojanowski JQ, et al. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer\u2019s disease. Brain. 2015;138:3373\u201385.","journal-title":"Brain"},{"key":"2376_CR61","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13195-015-0124-3","volume":"7","author":"H Kvartsberg","year":"2015","unstructured":"Kvartsberg H, Portelius E, Andreasson U, Brinkmalm G, Hellwig K, Lelental N, et al. Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer\u2019s disease patients and healthy controls. Alzheimers Res Ther. 2015;7:40.","journal-title":"Alzheimers Res Ther"},{"key":"2376_CR62","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.jalz.2015.05.012","volume":"11","author":"A De Vos","year":"2015","unstructured":"De Vos A, Jacobs D, Struyfs H, Fransen E, Andersson K, Portelius E, et al. C\u2010terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer\u2019s disease. Alzheimers Dement. 2015;11:1461\u20139.","journal-title":"Alzheimers Dement"},{"key":"2376_CR63","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jamaneurol.2016.0086","volume":"73","author":"R Tarawneh","year":"2016","unstructured":"Tarawneh R, D\u2019Angelo G, Crimmins D, Herries E, Griest T, Fagan AM, et al. Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer disease. JAMA Neurol. 2016;73:561.","journal-title":"JAMA Neurol"},{"key":"2376_CR64","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s00702-016-1597-3","volume":"123","author":"C Sanfilippo","year":"2016","unstructured":"Sanfilippo C, Forlenza O, Zetterberg H, Blennow K. Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer\u2019s disease and in mild cognitive impairment due to AD. J Neural Transm. 2016;123:1443\u20137.","journal-title":"J Neural Transm"},{"key":"2376_CR65","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.3233\/JAD-170368","volume":"59","author":"S Lista","year":"2017","unstructured":"For the Alzheimer Precision Medicine Initiative (APMI), Lista S, Toschi N, Baldacci F, Zetterberg H, Blennow K, et al. Cerebrospinal fluid neurogranin as a biomarker of neurodegenerative diseases: a cross-sectional study. J Alzheimers Dis. 2017;59:1327\u201334.","journal-title":"J Alzheimers Dis"},{"key":"2376_CR66","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.jalz.2018.01.012","volume":"14","author":"CL Sutphen","year":"2018","unstructured":"Sutphen CL, McCue L, Herries EM, Xiong C, Ladenson JH, Holtzman DM, et al. Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:869\u201379.","journal-title":"Alzheimers Dement"},{"key":"2376_CR67","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1136\/jnnp-2018-320155","volume":"90","author":"K Blennow","year":"2019","unstructured":"Blennow K, Diaz-Lucena D, Zetterberg H, Villar-Pique A, Karch A, Vidal E, et al. CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD. J Neurol Neurosurg Psychiatry. 2019;90:846\u201353.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2376_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nm.4269","volume":"23","author":"YC Wong","year":"2017","unstructured":"Wong YC, Krainc D. \u03b1-Synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med. 2017;23:1\u201313.","journal-title":"Nat Med"},{"key":"2376_CR69","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1093\/brain\/awx275","volume":"140","author":"M Colom-Cadena","year":"2017","unstructured":"Colom-Cadena M, Pegueroles J, Herrmann AG, Henstridge CM, Mu\u00f1oz L, Querol-Vilaseca M, et al. Synaptic phosphorylated \u03b1-synuclein in dementia with Lewy bodies. Brain. 2017;140:3204\u201314.","journal-title":"Brain"},{"key":"2376_CR70","doi-asserted-by":"publisher","first-page":"1255555","DOI":"10.1126\/science.1255555","volume":"349","author":"M Goedert","year":"2015","unstructured":"Goedert M. Alzheimer\u2019s and Parkinson\u2019s diseases: the prion concept in relation to assembled A\u03b2, tau, and \u03b1-synuclein. Science. 2015;349:1255555.","journal-title":"Science"},{"key":"2376_CR71","doi-asserted-by":"publisher","first-page":"S290","DOI":"10.1016\/j.jalz.2013.10.004","volume":"10","author":"S Slaets","year":"2014","unstructured":"Slaets S, Vanmechelen E, Le Bastard N, Decraemer H, Vandijck M, Martin J, et al. Increased CSF \u03b1\u2010synuclein levels in Alzheimer\u2019s disease: correlation with tau levels. Alzheimers Dement. 2014;10:S290\u20138.","journal-title":"Alzheimers Dement"},{"key":"2376_CR72","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/alzrt255","volume":"6","author":"O Hansson","year":"2014","unstructured":"Hansson O, Hall S, \u00d6hrfelt A, Zetterberg H, Blennow K, Minthon L, et al. Levels of cerebrospinal fluid \u03b1-synuclein oligomers are increased in Parkinson\u2019s disease with dementia and dementia with Lewy bodies compared to Alzheimer\u2019s disease. Alzheimers Res Ther. 2014;6:25.","journal-title":"Alzheimers Res Ther"},{"key":"2376_CR73","doi-asserted-by":"publisher","first-page":"e85443","DOI":"10.1371\/journal.pone.0085443","volume":"8","author":"N Mattsson","year":"2013","unstructured":"Mattsson N, Insel P, Tosun D, Zhang J, Jack Jr CR, Galasko D, et al. Effects of baseline CSF \u03b1-synuclein on regional brain atrophy rates in healthy elders, mild cognitive impairment and Alzheimer\u2019s disease. PLoS ONE. 2013;8:e85443.","journal-title":"PLoS ONE"},{"key":"2376_CR74","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.jalz.2018.06.3053","volume":"14","author":"A Vergallo","year":"2018","unstructured":"Vergallo A, Bun R, Toschi N, Baldacci F, Zetterberg H, Blennow K, et al. Association of cerebrospinal fluid \u03b1\u2010synuclein with total and phospho\u2010tau 181 protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer\u2019s disease biomarkers. Alzheimers Dement. 2018;14:1623\u201331.","journal-title":"Alzheimers Dement"},{"key":"2376_CR75","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1159\/000329763","volume":"31","author":"C Laske","year":"2011","unstructured":"Laske C, Fallgatter AJ, Stransky E, Hagen K, Berg D, Maetzler W. Decreased \u03b1-synuclein serum levels in patients with lewy body dementia compared to Alzheimer\u2019s disease patients and control subjects. Dement Geriatr Cogn Disord. 2011;31:413\u20136.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2376_CR76","doi-asserted-by":"publisher","first-page":"6451","DOI":"10.1007\/s12035-019-1531-4","volume":"56","author":"F Baldacci","year":"2019","unstructured":"Baldacci F, Daniele S, Piccarducci R, Giampietri L, Pietrobono D, Giorgi FS, et al. Potential diagnostic value of red blood cells \u03b1-synuclein heteroaggregates in Alzheimer\u2019s disease. Mol Neurobiol. 2019;56:6451\u20139.","journal-title":"Mol Neurobiol"},{"key":"2376_CR77","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3233\/JAD-201038","volume":"80","author":"S Daniele","year":"2021","unstructured":"Daniele S, Baldacci F, Piccarducci R, Palermo G, Giampietri L, Manca ML, et al. \u03b1-Synuclein heteromers in red blood cells of Alzheimer\u2019s disease and Lewy body dementia patients. J Alzheimers Dis. 2021;80:885\u201393.","journal-title":"J Alzheimers Dis"},{"key":"2376_CR78","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1074\/mcp.M116.059915","volume":"15","author":"P Oeckl","year":"2016","unstructured":"Oeckl P, Metzger F, Nagl M, Von Arnim CAF, Halbgebauer S, Steinacker P, et al. Alpha-, beta-, and gamma-synuclein quantification in cerebrospinal fluid by multiple reaction monitoring reveals increased concentrations in Alzheimer\u2032s and Creutzfeldt-Jakob disease but no alteration in synucleinopathies. Mol Cell Proteom. 2016;15:3126\u201338.","journal-title":"Mol Cell Proteom"},{"key":"2376_CR79","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s13195-022-01125-1","volume":"14","author":"P Mohaupt","year":"2022","unstructured":"Mohaupt P, Pons M-L, Vialaret J, Delaby C, Hirtz C, Lehmann S. \u03b2-Synuclein as a candidate blood biomarker for synaptic degeneration in Alzheimer\u2019s disease. Alzheimers Res Ther. 2022;14:179.","journal-title":"Alzheimers Res Ther"},{"key":"2376_CR80","doi-asserted-by":"publisher","first-page":"4896","DOI":"10.1002\/alz.13046","volume":"19","author":"P Oeckl","year":"2023","unstructured":"Oeckl P, Bluma M, Bucci M, Halbgebauer S, Chiotis K, Sandebring\u2010Matton A, et al. Blood \u03b2\u2010synuclein is related to amyloid PET positivity in memory clinic patients. Alzheimers Dement. 2023;19:4896\u2013907. alz.13046.","journal-title":"Alzheimers Dement"},{"key":"2376_CR81","doi-asserted-by":"publisher","first-page":"5095","DOI":"10.1002\/alz.13103","volume":"19","author":"P Oeckl","year":"2023","unstructured":"Oeckl P, Janelidze S, Halbgebauer S, Stomrud E, Palmqvist S, Otto M, et al. Higher plasma \u03b2\u2010synuclein indicates early synaptic degeneration in Alzheimer\u2019s disease. Alzheimers Dement. 2023;19:5095\u2013102. alz.13103","journal-title":"Alzheimers Dement"},{"key":"2376_CR82","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3233\/JAD-150060","volume":"47","author":"M Groblewska","year":"2015","unstructured":"Groblewska M, Muszy\u0144ski P, Wojtulewska-Supron A, Kulczy\u0144ska-Przybik A, Mroczko B. The role of visinin-like protein-1 in the pathophysiology of Alzheimer\u2019s disease. J Alzheimers Dis. 2015;47:17\u201332.","journal-title":"J Alzheimers Dis"},{"key":"2376_CR83","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1159\/000051244","volume":"12","author":"K-H Braunewell","year":"2001","unstructured":"Braunewell K-H, Riederer P, Spilker C, Gundelfinger ED, Bogerts B, Bernstein H-G. Abnormal localization of two neuronal calcium sensor proteins, visinin-like proteins (VILIPs)-1 and -3, in neocortical brain areas of Alzheimer disease patients. Dement Geriatr Cogn Disord. 2001;12:110\u20136.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2376_CR84","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1373\/clinchem.2008.104497","volume":"54","author":"J-M Lee","year":"2008","unstructured":"Lee J-M, Blennow K, Andreasen N, Laterza O, Modur V, Olander J, et al. The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin Chem. 2008;54:1617\u201323.","journal-title":"Clin Chem"},{"key":"2376_CR85","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, \u00d6hrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15:673\u201384.","journal-title":"Lancet Neurol"},{"key":"2376_CR86","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/ana.22448","volume":"70","author":"R Tarawneh","year":"2011","unstructured":"Tarawneh R, D\u2019Angelo G, Macy E, Xiong C, Carter D, Cairns NJ, et al. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol. 2011;70:274\u201385.","journal-title":"Ann Neurol"},{"key":"2376_CR87","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/jnc.12331","volume":"127","author":"X Luo","year":"2013","unstructured":"Luo X, Hou L, Shi H, Zhong X, Zhang Y, Zheng D, et al. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer\u2019s disease and dementia with Lewy bodies. J Neurochem. 2013;127:681\u201390.","journal-title":"J Neurochem"},{"key":"2376_CR88","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3233\/JAD-150705","volume":"50","author":"M Babi\u0107 Leko","year":"2016","unstructured":"Babi\u0107 Leko M, Borove\u010dki F, Dejanovi\u0107 N, Hof PR, \u0160imi\u0107 G. Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer\u2019s disease early detection and differential diagnosis in patients with mild cognitive impairment. J Alzheimers Dis. 2016;50:765\u201378.","journal-title":"J Alzheimers Dis"},{"key":"2376_CR89","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1001\/jamaneurol.2015.0202","volume":"72","author":"R Tarawneh","year":"2015","unstructured":"Tarawneh R, Head D, Allison S, Buckles V, Fagan AM, Ladenson JH, et al. Cerebrospinal fluid markers of neurodegeneration and rates of brain atrophy in early Alzheimer disease. JAMA Neurol. 2015;72:656.","journal-title":"JAMA Neurol"},{"key":"2376_CR90","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1212\/WNL.0b013e318248e568","volume":"78","author":"R Tarawneh","year":"2012","unstructured":"Tarawneh R, Lee J-M, Ladenson JH, Morris JC, Holtzman DM. CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology. 2012;78:709\u201319.","journal-title":"Neurology"},{"key":"2376_CR91","doi-asserted-by":"publisher","first-page":"226ra30","DOI":"10.1126\/scitranslmed.3007901","volume":"6","author":"AM Fagan","year":"2014","unstructured":"Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TLS, et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer\u2019s disease. Sci Transl Med. 2014;6:226ra30.","journal-title":"Sci Transl Med"},{"key":"2376_CR92","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40520-019-01458-2","volume":"33","author":"IA Mavroudis","year":"2021","unstructured":"Mavroudis IA, Petridis F, Chatzikonstantinou S, Karantali E, Kazis D. A meta-analysis on the levels of VILIP-1 in the CSF of Alzheimer\u2019s disease compared to normal controls and other neurodegenerative conditions. Aging Clin Exp Res. 2021;33:265\u201372.","journal-title":"Aging Clin Exp Res"},{"key":"2376_CR93","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13195-016-0208-8","volume":"8","author":"A \u00d6hrfelt","year":"2016","unstructured":"\u00d6hrfelt A, Brinkmalm A, Dumurgier J, Brinkmalm G, Hansson O, Zetterberg H, et al. The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer\u2019s disease. Alzheimers Res Ther. 2016;8:41.","journal-title":"Alzheimers Res Ther"},{"key":"2376_CR94","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fnsyn.2016.00007","volume":"8","author":"F Antonucci","year":"2016","unstructured":"Antonucci F, Corradini I, Fossati G, Tomasoni R, Menna E, Matteoli M. SNAP-25, a known presynaptic protein with emerging postsynaptic functions. Front Synaptic Neurosci. 2016;8:7.","journal-title":"Front Synaptic Neurosci"},{"key":"2376_CR95","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1750-1326-9-53","volume":"9","author":"A Brinkmalm","year":"2014","unstructured":"Brinkmalm A, Brinkmalm G, Honer WG, Fr\u00f6lich L, Hausner L, Minthon L, et al. SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer\u2019s disease. Mol Neurodegener. 2014;9:53.","journal-title":"Mol Neurodegener"},{"key":"2376_CR96","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-018-0407-6","volume":"10","author":"H Zhang","year":"2018","unstructured":"The Alzheimer\u2019s Disease Neuroimaging Initiative, Zhang H, Therriault J, Kang MS, Ng KP, Pascoal TA, et al. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer\u2019s disease. Alzheimers Res Ther. 2018;10:80.","journal-title":"Alzheimers Res Ther"},{"key":"2376_CR97","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jalz.2018.12.019","volume":"15","author":"SE Schindler","year":"2019","unstructured":"Schindler SE, Li Y, Todd KW, Herries EM, Henson RL, Gray JD, et al. Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer\u2019s disease. Alzheimers Dement. 2019;15:655\u201365.","journal-title":"Alzheimers Dement"},{"key":"2376_CR98","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13195-023-01212-x","volume":"15","author":"S Das","year":"2023","unstructured":"Das S, Goossens J, Jacobs D, Dewit N, Pijnenburg YAL, In \u2018T Veld SGJG, et al. Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer\u2019s disease and frontotemporal dementia. Alzheimers Res Ther. 2023;15:62.","journal-title":"Alzheimers Res Ther"},{"key":"2376_CR99","doi-asserted-by":"publisher","first-page":"e92624","DOI":"10.1371\/journal.pone.0092624","volume":"9","author":"N Rosskothen-Kuhl","year":"2014","unstructured":"Rosskothen-Kuhl N, Illing R-B. Gap43 transcription modulation in the adult brain depends on sensory activity and synaptic cooperation. PLoS ONE. 2014;9:e92624.","journal-title":"PLoS ONE"},{"key":"2376_CR100","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/S0166-2236(96)10072-2","volume":"20","author":"LI Benowitz","year":"1997","unstructured":"Benowitz LI, Routtenberg A. GAP-43: an intrinsic determinant of neuronal development and plasticity. Trends Neurosci. 1997;20:84\u201391.","journal-title":"Trends Neurosci"},{"key":"2376_CR101","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jalz.2018.08.006","volume":"15","author":"\u00c5 Sandelius","year":"2019","unstructured":"Sandelius \u00c5, Portelius E, K\u00e4ll\u00e9n \u00c5, Zetterberg H, Rot U, Olsson B, et al. Elevated CSF GAP\u201043 is Alzheimer\u2019s disease specific and associated with tau and amyloid pathology. Alzheimers Dement. 2019;15:55\u201364.","journal-title":"Alzheimers Dement"},{"key":"2376_CR102","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00702-021-02411-2","volume":"129","author":"N G\u00f3mez De San Jos\u00e9","year":"2022","unstructured":"G\u00f3mez De San Jos\u00e9 N, Massa F, Halbgebauer S, Oeckl P, Steinacker P, Otto M. Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration. J Neural Transm. 2022;129:207\u201330.","journal-title":"J Neural Transm"},{"key":"2376_CR103","doi-asserted-by":"publisher","first-page":"e23798","DOI":"10.7554\/eLife.23798","volume":"6","author":"M-F Xiao","year":"2017","unstructured":"Xiao M-F, Xu D, Craig MT, Pelkey KA, Chien C-C, Shi Y, et al. NPTX2 and cognitive dysfunction in Alzheimer\u2019s Disease. eLife. 2017;6:e23798.","journal-title":"eLife"},{"key":"2376_CR104","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13024-020-00398-0","volume":"15","author":"O Belbin","year":"2020","unstructured":"Belbin O, Xiao M-F, Xu D, Carmona-Iragui M, Pegueroles J, Benejam B, et al. Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer\u2019s disease-related inhibitory circuit dysfunction in adults with Down syndrome. Mol Neurodegener. 2020;15:46.","journal-title":"Mol Neurodegener"},{"key":"2376_CR105","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/ana.26725","volume":"94","author":"A Soldan","year":"2023","unstructured":"Soldan A, Oh S, Ryu T, Pettigrew C, Zhu Y, Moghekar A, et al. NPTX2 in cerebrospinal fluid predicts the progression from normal cognition to Mild Cognitive Impairment. Ann Neurol. 2023;94:620\u201331. ana.26725","journal-title":"Ann Neurol"},{"key":"2376_CR106","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/j.neurobiolaging.2011.09.007","volume":"32","author":"EM Reiman","year":"2011","unstructured":"Reiman EM. Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer\u2019s disease-modifying treatments. Neurobiol Aging. 2011;32:S44\u20137.","journal-title":"Neurobiol Aging"},{"key":"2376_CR107","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nn.4492","volume":"20","author":"ER Zimmer","year":"2017","unstructured":"Zimmer ER, Parent MJ, Souza DG, Leuzy A, Lecrux C, Kim H-I, et al. [18F]FDG PET signal is driven by astroglial glutamate transport. Nat Neurosci. 2017;20:393\u20135.","journal-title":"Nat Neurosci"},{"key":"2376_CR108","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1176\/appi.ajp.159.5.738","volume":"159","author":"GE Alexander","year":"2002","unstructured":"Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer\u2019s disease treatment studies. Am J Psychiatry. 2002;159:738\u201345.","journal-title":"Am J Psychiatry"},{"key":"2376_CR109","doi-asserted-by":"publisher","first-page":"864514","DOI":"10.3389\/fnins.2022.864514","volume":"16","author":"R Rossi","year":"2022","unstructured":"Rossi R, Arjmand S, B\u00e6rentzen SL, Gjedde A, Landau AM. Synaptic vesicle glycoprotein 2A: features and functions. Front Neurosci. 2022;16:864514.","journal-title":"Front Neurosci"},{"key":"2376_CR110","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-021-00384-5","volume":"8","author":"C Cawthorne","year":"2021","unstructured":"Cawthorne C, Maguire P, Mercier J, Sciberras D, Serdons K, Bormans G, et al. Human biodistribution and dosimetry of [11C]-UCB-J, a PET radiotracer for imaging synaptic density. EJNMMI Phys. 2021;8:37.","journal-title":"EJNMMI Phys"},{"key":"2376_CR111","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1001\/jamaneurol.2018.1836","volume":"75","author":"M-K Chen","year":"2018","unstructured":"Chen M-K, Mecca AP, Naganawa M, Finnema SJ, Toyonaga T, Lin S-F, et al. Assessing synaptic density in Alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging. JAMA Neurol. 2018;75:1215\u201324.","journal-title":"JAMA Neurol"},{"key":"2376_CR112","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/s00259-019-04461-x","volume":"47","author":"C Bastin","year":"2020","unstructured":"Bastin C, Bahri MA, Meyer F, Manard M, Delhaye E, Plenevaux A, et al. In vivo imaging of synaptic loss in Alzheimer\u2019s disease with [18F]UCB-H positron emission tomography. Eur J Nucl Med Mol Imaging. 2020;47:390\u2013402.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2376_CR113","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1007\/s11307-019-01428-0","volume":"22","author":"S Patel","year":"2020","unstructured":"Patel S, Knight A, Krause S, Teceno T, Tresse C, Li S, et al. Preclinical in vitro and in vivo characterization of synaptic vesicle 2A\u2013targeting compounds amenable to F-18 labeling as potential PET radioligands for imaging of synapse integrity. Mol Imaging Biol. 2020;22:832\u201341.","journal-title":"Mol Imaging Biol"},{"key":"2376_CR114","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s11307-018-1260-5","volume":"21","author":"CC Constantinescu","year":"2019","unstructured":"Constantinescu CC, Tresse C, Zheng M, Gouasmat A, Carroll VM, Mistico L, et al. Development and in vivo preclinical imaging of fluorine-18-labeled synaptic vesicle protein 2A (SV2A) PET tracers. Mol Imaging Biol. 2019;21:509\u201318.","journal-title":"Mol Imaging Biol"},{"key":"2376_CR115","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.bcp.2013.12.028","volume":"88","author":"SW Scheff","year":"2014","unstructured":"Scheff SW, Neltner JH, Nelson PT. Is synaptic loss a unique hallmark of Alzheimer\u2019s disease? Biochem Pharm. 2014;88:517\u201328.","journal-title":"Biochem Pharm"},{"key":"2376_CR116","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13195-022-01014-7","volume":"14","author":"A Vrillon","year":"2022","unstructured":"Vrillon A, Mouton-Liger F, Martinet M, Cognat E, Hourregue C, Dumurgier J, et al. Plasma neuregulin 1 as a synaptic biomarker in Alzheimer\u2019s disease: a discovery cohort study. Alzheimers Res Ther. 2022;14:71.","journal-title":"Alzheimers Res Ther"},{"key":"2376_CR117","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1096\/fj.201600816R","volume":"30","author":"EJ Goetzl","year":"2016","unstructured":"Goetzl EJ, Kapogiannis D, Schwartz JB, Lobach IV, Goetzl L, Abner EL, et al. Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer\u2019s disease. FASEB J. 2016;30:4141\u20138.","journal-title":"FASEB J"},{"key":"2376_CR118","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1096\/fj.201700731R","volume":"32","author":"EJ Goetzl","year":"2018","unstructured":"Goetzl EJ, Abner EL, Jicha GA, Kapogiannis D, Schwartz JB. Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer\u2019s disease. FASEB J. 2018;32:888\u201393.","journal-title":"FASEB J"},{"key":"2376_CR119","doi-asserted-by":"publisher","first-page":"e036990","DOI":"10.1136\/bmjopen-2020-036990","volume":"10","author":"M He","year":"2020","unstructured":"He M, Sun L, Cao W, Yin C, Sun W, Liu P, et al. Association between plasma exosome neurogranin and brain structure in patients with Alzheimer\u2019s disease: a protocol study. BMJ Open. 2020;10:e036990.","journal-title":"BMJ Open"},{"key":"2376_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-0801-2","volume":"10","author":"W Liu","year":"2020","unstructured":"Liu W, Lin H, He X, Chen L, Dai Y, Jia W, et al. Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer\u2019s disease and mild cognitive impairment. Transl Psychiatry. 2020;10:125.","journal-title":"Transl Psychiatry"},{"key":"2376_CR121","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/mds.29287","volume":"38","author":"J Nilsson","year":"2023","unstructured":"Nilsson J, Constantinescu J, Nellg\u00e5rd B, Jakobsson P, Brum WS, Gobom J, et al. Cerebrospinal fluid biomarkers of synaptic dysfunction are altered in Parkinson\u2019s disease and related disorders. Mov Disord. 2023;38:267\u201377.","journal-title":"Mov Disord"},{"key":"2376_CR122","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13195-022-01042-3","volume":"14","author":"A Sogorb-Esteve","year":"2022","unstructured":"Sogorb-Esteve A, Nilsson J, Swift IJ, Heller C, Bocchetta M, Russell LL, et al. Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia. Alzheimers Res Ther. 2022;14:118.","journal-title":"Alzheimers Res Ther"},{"key":"2376_CR123","doi-asserted-by":"publisher","first-page":"100542","DOI":"10.1016\/j.mcpro.2023.100542","volume":"22","author":"C Hurst","year":"2023","unstructured":"Hurst C, Pugh DA, Abreha MH, Duong DM, Dammer EB, Bennett DA, et al. Integrated proteomics to understand the role of neuritin (NRN1) as a mediator of cognitive resilience to Alzheimer\u2019s disease. Mol Cell Proteom. 2023;22:100542.","journal-title":"Mol Cell Proteom"},{"key":"2376_CR124","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/s41591-023-02476-4","volume":"29","author":"ECB Johnson","year":"2023","unstructured":"Johnson ECB, Bian S, Haque RU, Carter EK, Watson CM, Gordon BA, et al. Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer\u2019s disease. Nat Med. 2023;29:1979\u201388.","journal-title":"Nat Med"},{"key":"2376_CR125","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.3390\/s23094184","volume":"23","author":"AG Vrahatis","year":"2023","unstructured":"Vrahatis AG, Skolariki K, Krokidis MG, Lazaros K, Exarchos TP, Vlamos P. Revolutionizing the early detection of Alzheimer\u2019s disease through non-invasive biomarkers: the role of artificial intelligence and deep learning. Sensors. 2023;23:4184.","journal-title":"Sensors"},{"key":"2376_CR126","unstructured":"Borchert RJ, Azevedo T, Badhwar A, Bernal J, Betts M, Bruffaerts R, et al. Artificial intelligence for diagnostic and prognostic neuroimaging in dementia: a systematic review. Alzheimers Dement. 2023:alz.13412."},{"key":"2376_CR127","doi-asserted-by":"crossref","unstructured":"Winchester LM, Harshfield EL, Shi L, Badhwar A, Khleifat AA, Clarke N, et al. Artificial intelligence for biomarker discovery in Alzheimer\u2019s disease and dementia. Alzheimers Dement. 2023:alz.13390.","DOI":"10.1002\/alz.13390"},{"key":"2376_CR128","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/jpm10020034","volume":"10","author":"PM Rossini","year":"2020","unstructured":"Rossini PM, Miraglia F, Al\u00f9 F, Cotelli M, Ferreri F, Iorio RD, et al. Neurophysiological hallmarks of neurodegenerative cognitive decline: the study of brain connectivity as a biomarker of early dementia. J Pers Med. 2020;10:34.","journal-title":"J Pers Med"},{"key":"2376_CR129","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3233\/JAD-180063","volume":"63","author":"PK Mandal","year":"2018","unstructured":"Mandal PK, Shukla D. Brain metabolic, structural, and behavioral pattern learning for early predictive diagnosis of Alzheimer\u2019s disease. J Alzheimers Dis. 2018;63:935\u20139.","journal-title":"J Alzheimers Dis"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02376-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02376-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02376-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T11:22:12Z","timestamp":1717586532000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02376-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":129,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["2376"],"URL":"https:\/\/doi.org\/10.1038\/s41380-023-02376-6","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,16]]},"assertion":[{"value":"6 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EE is the unique owner of 2E Science, a for-profit private scientific company. Neither EE nor 2E Science have any commercial interest or financial tie in relation with this article. BPI is an employee at Chiesi Farmaceutici. He is listed among the inventors of a number of Chiesi Farmaceutici\u2019s patents of anti-Alzheimer drugs. HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). SL, AS-L, NBM, AG, SL-O, JM-H, NM, CI, FC, and RN declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}